Recurrent Glioblastoma Clinical Trial
Official title:
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma
Verified date | March 2024 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | August 31, 2025 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Documented informed consent of the participant and/or legally authorized representative. Assent, when appropriate, will be obtained per institutional guidelines. Note: For research participants who do not speak English, a short form consent may be used with a COH certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated main consent is processed. However, the research participant is allowed to proceed with surgery/rickham placement and CAR T cell infusion only after the translated main consent form is signed. - Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If unavailable, exceptions may be granted with study principal investigator (PI) approval - Karnofsky performance status (KPS) >= 60% - Eastern Cooperative Oncology Group (ECOG) =< 2 - Life expectancy >= 4 weeks - Participant has a prior histologically-confirmed diagnosis of a grade IV glioblastoma, or has a prior histologically-confirmed diagnosis of a grade II or III malignant brain tumors and now has radiographic progression consistent with a grade IV glioblastoma - Relapsed disease: radiographic evidence of recurrence/progression of measurable disease after standard therapy, and >= 12 weeks after completion of front-line radiation therapy - City of Hope (COH) Clinical Pathology confirms matrix metalloproteinase (MMP)2+ tumor expression by immunohistochemistry (>= 20% moderate/high MMP2 [2+/3+]) - No known contraindications to leukapheresis, steroids, or tocilizumab - White blood cell (WBC) > 2000 /dl (or absolute neutrophil count [ANC] >= 1,000/mm^3) (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Platelets >= 75,000/mm^3 (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Hemoglobin >= 8 g/dl (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Total bilirubin =< 1.5 upper limit of normal (ULN) (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Aspartate aminotransferase (AST) =< 2.5 x ULN (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Alanine aminotransferase (ALT) =< 2.5 x ULN (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Serum creatinine =< 1.6 mg/dL (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Oxygen (O2) saturation >= 95% on room air (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo (to be performed within 14 days prior to leukapheresis unless otherwise stated) - Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (to be performed within 14 days prior to leukapheresis unless otherwise stated) - If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required - Agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of CAR T cells - Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only) Exclusion Criteria: - Prior and concomitant therapies - Owing to higher frequency of wound-related complications, participants who are within 3 months of having received prior bevacizumab therapy at the time of enrollment are excluded. - Participant has not yet recovered from toxicities of prior therapy - Other illnesses or conditions - Uncontrolled seizure activity and/or clinically evident progressive encephalopathy - History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent - Active diarrhea - Clinically significant uncontrolled illness - Active infection requiring antibiotics - Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection - Other active malignancy - Females only: Pregnant or breastfeeding - Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures - Noncompliance - Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics) |
Country | Name | City | State |
---|---|---|---|
United States | City of Hope Medical Center | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose limiting toxicity (DLT) | Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 5.0). Rate and associated 90% Clopper and Pearson binomial confidence limits (90% confidence interval) will be estimated for participants experiencing DLTs at the recommended phase 2 dose schedule. Tables will be created to summarize all toxicities and side effects by dose, time post treatment, organ, severity, and arm. 2. Cytokine Release Syndrome (CRS) 3. All other toxicities. | 28 days | |
Secondary | Chimeric antigen receptor (CAR) T cell | Will assess its levels and phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF) (absolute number per ul by flowcytometry). Statistical and graphical methods will be used. | 15 years | |
Secondary | Endogenous T cell | Will assess its level and phenotype detected in TCF, PB, and CSF (absolute number per ul by flowcytometry). Statistical and graphical methods will be used. | 15 years | |
Secondary | Cytokine levels in TCF, PB and CSF | 15 years | ||
Secondary | Progression free survival time | At 6 months | ||
Secondary | Disease response | Will be assessed by modified Response Assessment in Neuro-Oncology Criteria (RANO) criteria with the need for bevacizumab as an additional indicator of progression. | At 6 months | |
Secondary | Overall survival (OS) | Kaplan Meier methods will be used to estimate median OS and graph the results. | At 9 months | |
Secondary | CAR T cells detected in tumor tissue | Will be assessed by immunohistochemistry. | 15 years | |
Secondary | Chlorotoxin-targeted antigen expression levels in tumor tissue | Will assess the pathology H score. | 15 years | |
Secondary | Biomathematical modeling of tumor growth | Will assess perfusion and growth parameters based on serial brain magnetic resonance imaging (MRI)s. | 15 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05577091 -
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
|
Phase 1 | |
Recruiting |
NCT05284643 -
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
|
N/A | |
Recruiting |
NCT05039281 -
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04988750 -
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
|
N/A | |
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Completed |
NCT00503204 -
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
|
Phase 1 | |
Completed |
NCT03216499 -
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
|
Phase 2 | |
Not yet recruiting |
NCT04717999 -
Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
|
N/A | |
Not yet recruiting |
NCT05540275 -
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
|
Phase 2 | |
Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT04044937 -
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
|
Phase 2 | |
Recruiting |
NCT04888611 -
Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma
|
Phase 2 | |
Completed |
NCT00390299 -
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 1 | |
Recruiting |
NCT05463848 -
Surgical Pembro +/- Olaparib w TMZ for rGBM
|
Phase 2 | |
Active, not recruiting |
NCT04479241 -
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT00777153 -
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
|
Phase 3 | |
Withdrawn |
NCT05017610 -
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
|
Early Phase 1 | |
Recruiting |
NCT04323046 -
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
|
Phase 1 | |
Active, not recruiting |
NCT05324501 -
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
|
Phase 1 | |
Withdrawn |
NCT05666349 -
Reirradiation and Niraparib in Patients With Recurrent Glioblastoma
|
Phase 1 |